Plain-English translation of NCT06773598 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Prostate Cancer research guide โResearchers have developed a machine learning tool โ a type of artificial intelligence trained to recognize patterns โ that analyzes MRI scan images to predict whether a prostate cancer is clinically significant (meaning it's serious and likely needs treatment). This study will test whether this tool works accurately by analyzing MRI scans and biopsy results from about 1,100 men, helping doctors make better decisions about which patients need treatment.
Not all prostate cancers are dangerous โ some grow slowly and may never harm a man. The challenge is figuring out which ones are serious. This study exists to see if this new computer tool can accurately identify dangerous prostate cancers, which would help doctors avoid treating men who don't need it and make sure those who do get the care they need.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you join, researchers will use your existing MRI scan images and medical information โ some collected in the past and some collected as part of this study going forward. Doctors will use the new computer tool to analyze your scans to predict whether your prostate cancer is serious. If you undergo prostate biopsy or surgery as part of your regular care, those results will also be included to help the researchers validate how accurate the tool is. You won't receive any new experimental treatment; the study is focused on testing whether this computer tool works well.
AI-generated summary from trial data ยท Jun 3, 2026 ยท Not medical advice
Italy
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment target
~1,100 participants
Started
May 2024
Primary completion
October 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Caterina Gaudiano, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.